甲基(3S)-2-氮杂双环[2.2.2]辛烷-3-羧酸酯 | 736111-77-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甲基(3S)-2-氮杂双环[2.2.2]辛烷-3-羧酸酯
• 英文名称: 2-aza-bicyclo[2.2.2]octane-3S-carboxylic acid methyl ester
• 英文别名: (S)-Methyl 2-azabicyclo[2.2.2]octane-3-carboxylate；methyl (3S)-2-azabicyclo[2.2.2]octane-3-carboxylate
• CAS: 736111-77-6
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: ICCFVKYDGHSTCZ-RRQHEKLDSA-N

物化性质

• 沸点：
  236.5±23.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基(3S)-2-氮杂双环[2.2.2]辛烷-3-羧酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-3-{4-[(3,5-Dichloro-pyridine-4-carbonyl)-amino]-phenyl}-2-{[(R)-2-(3-phenyl-propionyl)-2-aza-bicyclo[2.2.2]octane-3-carbonyl]-amino}-propionic acid
  参考文献：
  名称：

  Aza-bicyclic amino acid carboxamides as α4β1/α4β7 integrin receptor antagonists

  摘要：

  A series of N-carboxy, N-alkyl, and N-carboxamido azabicyclo[2.2.2]octane carboxamides were prepared and assayed for inhibition Of alpha(4)beta(1)-VCAM-1 and alpha(4)beta(7)-MAdCAM-1 interactions. Potency and alpha(4)beta(1)/alpha(4)beta(7) selectivity were sensitive to the substituent R-1-R-3 in the structures 6, 7, and 8. Several compounds demonstrated low nanomolar balanced alpha(4)beta(1)/alpha(4)beta(7) in vitro activity. Two compounds were selected for in vivo leukocytosis studies and demonstrated increases in circulating lymphocytes up to 250% over control. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.022
• 作为产物：
  描述：

  2-(1-(R)-phenethyl)-2-(S)-azabicyclo[2.2.2]oct-5-ene-3-carboxylic acid benzyl ester 在 5%-palladium/activated carbon 甲醇 、 氢气 作用下， 以 甲醇 、 正己烷 、 水 、 苯 为溶剂， 25.0 ℃ 、310.27 kPa 条件下， 反应 4.0h， 生成 甲基(3S)-2-氮杂双环[2.2.2]辛烷-3-羧酸酯
  参考文献：
  名称：

  WO2008/73987

  摘要：

  公开号：

文献信息

• SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS
  申请人：Ruebsam Frank

  公开号：US20080214529A1

  公开（公告）日：2008-09-04

  The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

  本发明涉及饱和融合[1,2-b]吡啶嗪化合物和含有这种化合物的制药组合物，其可用于治疗丙型肝炎病毒感染。
• [EN] SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS<br/>[FR] COMPOSÉS [1,2-B]PYRIDAZINONE CONDENSÉS SATURÉS
  申请人：ANADYS PHARMACEUTICALS INC

  公开号：WO2008073987A1

  公开（公告）日：2008-06-19

  [EN] The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
  [FR] L'invention concerne des composés [1,2-b]pyridazinone condensés saturés et des compositions pharmaceutiques contenant de tels composés qui sont utiles dans le traitement d'infections par le virus de l'hépatite C.
• Aza-bicyclic amino acid carboxamides as α4β1/α4β7 integrin receptor antagonists
  作者：Alexey B. Dyatkin、Yong Gong、Tamara A. Miskowski、Edward S. Kimball、Stephen M. Prouty、M. Carolyn Fisher、Rosemary J. Santulli、Craig R. Schneider、Nathaniel H. Wallace、Pamela J. Hornby、Craig Diamond、William A. Kinney、Bruce E. Maryanoff、Bruce P. Damiano、Wei He

  DOI：10.1016/j.bmc.2005.07.022

  日期：2005.12

  A series of N-carboxy, N-alkyl, and N-carboxamido azabicyclo[2.2.2]octane carboxamides were prepared and assayed for inhibition Of alpha(4)beta(1)-VCAM-1 and alpha(4)beta(7)-MAdCAM-1 interactions. Potency and alpha(4)beta(1)/alpha(4)beta(7) selectivity were sensitive to the substituent R-1-R-3 in the structures 6, 7, and 8. Several compounds demonstrated low nanomolar balanced alpha(4)beta(1)/alpha(4)beta(7) in vitro activity. Two compounds were selected for in vivo leukocytosis studies and demonstrated increases in circulating lymphocytes up to 250% over control. (c) 2005 Elsevier Ltd. All rights reserved.
• WO2008/73987
  申请人：——

  公开号：——

  公开（公告）日：——